Literature DB >> 18276651

Statins and sepsis.

F Gao1, L Linhartova, A McD Johnston, D R Thickett.   

Abstract

Severe sepsis and septic shock is common and frequently fatal. Over the last few years, the primary treatments demonstrated to improve outcome from several major clinical trials have finally emerged. However, translating these recent therapeutic advances to routine clinical practice has proven controversial, and new approaches of additional strategies are continued to be developed. Given their pleiotropic effects related to many pathophysiological determinants of sepsis, statin therapy could be the next step in the search for adjuvant therapy. A future challenge may be to test both the efficacy and the safety by large randomized controlled clinical trials ascertaining the effects of statins administered at the onset of sepsis and in patients with severe sepsis or septic shock admitted into intensive care units.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276651     DOI: 10.1093/bja/aem406

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  22 in total

Review 1.  [New aspects of perioperative statin therapy].

Authors:  N Butte; B W Böttiger; O Liakopoulos; P Teschendorf
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

2.  Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production.

Authors:  Ping-Chih Ho; Kun-Che Chang; Ya-Shan Chuang; Li-Na Wei
Journal:  FASEB J       Date:  2011-02-01       Impact factor: 5.191

3.  Effect of statins on outcomes in immunosuppressed patients with bloodstream infection.

Authors:  D Viasus; C Gudiol; N Fernández-Sabé; I Cabello; C Garcia-Vidal; M Cisnal; R Duarte; M Antonio; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-12       Impact factor: 3.267

4.  Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.

Authors:  Jie Liao; Yeon T Chung; Allison L Yang; Meng Zhang; Haonan Li; Wanying Zhang; Liang Yan; Guang-Yu Yang
Journal:  Mol Carcinog       Date:  2012-04-30       Impact factor: 4.784

5.  PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure.

Authors:  Barbara Rinaldi; Maria Donniacuo; Emanuela Esposito; Annalisa Capuano; Loredana Sodano; Emanuela Mazzon; Donatella Di Palma; Irene Paterniti; Salvatore Cuzzocrea; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury.

Authors:  Daryl J Kor; Remzi Iscimen; Murat Yilmaz; Michael J Brown; Daniel R Brown; Ognjen Gajic
Journal:  Intensive Care Med       Date:  2009-01-31       Impact factor: 17.440

7.  A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis.

Authors:  Peter S Kruger; Noelle M Freir; Bala Venkatesh; Thomas A Robertson; Michael S Roberts; Mark Jones
Journal:  Intensive Care Med       Date:  2008-11-26       Impact factor: 17.440

8.  Chronic Statin Use and Long-Term Rates of Sepsis: A Population-Based Cohort Study.

Authors:  Henry E Wang; Russell Griffin; Nathan I Shapiro; George Howard; Monika M Safford
Journal:  J Intensive Care Med       Date:  2014-09-15       Impact factor: 3.510

9.  Rosuvastatin for sepsis-associated acute respiratory distress syndrome.

Authors:  Jonathon D Truwit; Gordon R Bernard; Jay Steingrub; Michael A Matthay; Kathleen D Liu; Timothy E Albertson; Roy G Brower; Carl Shanholtz; Peter Rock; Ivor S Douglas; Bennett P deBoisblanc; Catherine L Hough; R Duncan Hite; B Taylor Thompson
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.